ALSO NOTED: Auxilium enrolling patients; Wyeth wins conditional approval; and much more...

> Auxilium Pharmaceuticals of Malvern, PA has begun enrolling patients for a Phase III trial of AA2600, an experimental therapy for hypogodanism, testosterone deficiency. "Delivering testosterone replacement therapy through an oral transmucosal film may provide men efficacy results equivalent to approved transdermal treatments but with quicker release of testosterone and lower dosing," said Dr. Jyrki Mattila, Auxilium's EVP for R&D. Report

> Wyeth has won conditional FDA approval for its low-dose contraceptive Lybrel, but says it is confident that it can satisfy the agency's requests for more data and analyses. Report

> Keryx Biopharmaceuticals says a mid-stage trial of its experimental Zerenex delivered positive results for end stage renal disease. Release

> Cipher Pharmaceuticals has submitted an NDA for once-daily Tramadol. Report

> VaxGen has raised $79 million through the sale of its interest in an overseas facility. Release

> Johnson & Johnson has licensed the U.S. rights to Sinclair Pharma's gum disease rinse Decapinol. Report

> Pharmos has begun dosing in a Phase IIa of Cannabinor for pain. Report

And Finally... Top European pharma executives harshly criticized a new set of European price controls, saying that they are stifling the continent's drug industry. Article